DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment
During the 2024 ASCO Annual Meeting, investigators shared preliminary and updated findings from 2 phase 3 studies evaluating the HER2-directed antibody-drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) against different comparators in …